

Get in the KNOW
on LA Startups & Tech
X
Photo by Dima Solomin on Unsplash
Why Is Every Social Media Company Pivoting to TikTok?
Kristin Snyder
Kristin Snyder is dot.LA's 2022/23 Editorial Fellow. She previously interned with Tiger Oak Media and led the arts section for UCLA's Daily Bruin.
TikTok’s algorithm is dominating the social media landscape.
Instagram recently increased its push to re-create TikTok’s success, with the company changing its platform to prioritize Reels. Facebook is also shifting its interface to prioritize algorithmic content over posts from friends—and as companies try to increase user engagement and ad revenue, some users long for distinctly different platforms. Both Kim Kardashian and Kylie Jenner shared a petition via Instagram stories urging the app to “stop trying to be tiktok.” The petition, which has over 160,000 signatures, was launched by photographer Tati Bruening and requests a return to a focus on photos.
“We have TikTok for a reason, and let’s face it, the only reels uploaded are recycled TikToks and content that the world has already seen,” Bruening wrote in the petition. “What’s innovative and unique about old stale content? Nothing!”
Instagram head Adam Mosseri took to Reels Tuesday morning to reassure users that the app will still support photos, even though “more and more of Instagram is going to become video over time,” he said.
Evan Britton, founder of Santa Monica-based Famous Birthdays, told dot.LA that the pivot to video stems from advertising trends. It’s harder for advertisers to place a video ad between photos than between videos. Switching mediums allows Instagram to make more revenue per user, Britton said. Some analysts believe Reels has the potential to surpass TikTok in ad revenue.
Britton also said Instagram’s previous model of chronological, friend-based feeds would eventually lead to a lack of content to view, whereas algorithms provide an endless loop of content and increase engagement.
Though users are more comfortable controlling their feeds, Britton said drawing in viewers through the algorithm helps with post interaction. Gen Z, in particular, uses TikTok more than other social media platforms because of its interest-driven algorithm. He said pushback stems from the late-in-the-game shift from Instagram’s original interface. Despite complaints, Britton believes there is no practical reason for Meta to abandon its commitment to video.
“When people open up Instagram and it is slowly morphing, more and more, into Tik Tok, people are going to stay longer,” Britton said. “If people didn't love Instagram so much they wouldn’t be concerned about it changing.”
Major influencers like the Kardashian-Jenner clan probably want their preferred social media platforms to have distinct differences, as do the microinfluencers who have struggled to navigate the ever-changing algorithms. But, Kim, there’s people that are dying—including social media companies that have to make a profit off of free content.
“It's going to [result in] higher revenue per user for watching videos, and there'll be more engagement in time in the app because there's an endless supply of content because it's based on interests versus who you follow,” Britton said.
From Your Site Articles
- TikTok, Snapchat, YouTube and Facebook: Who's Paying What for ... ›
- Instagram Updates Algorithm to Fight Reposted Content - dot.LA ›
- Facebook’s ‘Pivot to TikTok’ - dot.LA ›
- Meta Is Hiring More AR/ VR Employees in LA, Despite Layoffs - dot.LA ›
- Creators Struggle To Keep Up With Instagram's Pivot To Video - dot.LA ›
- How to Game TikTok's Algorithm - dot.LA ›
- Everything To Know About TikTok's FYP Algorithm - dot.LA ›
Related Articles Around the Web
Kristin Snyder
Kristin Snyder is dot.LA's 2022/23 Editorial Fellow. She previously interned with Tiger Oak Media and led the arts section for UCLA's Daily Bruin.
https://twitter.com/ksnyder_db
VivoSense Raises $25 Million to Collect Wearable Data for Clinical Drug Trials
05:00 PM | March 30, 2022
Image courtesy of VivoSense
As the CEO of Sarepta Therapeutics from 2011 to 2015, Chris Garabedian led a biotech firm striving to find cures for rare diseases. But because such diseases usually affect only a small population, it became difficult to collect a robust dataset on patients during clinical trials—the lengthy and rigorous process by which drugs are able to receive Food and Drug Administration approval for safety and efficacy.
At the time, Garabedian wanted to see if Sarepta could collect more data on its trial patients through the use of wearable sensors—but in 2011, as he recalled to dot.LA, it was hard to find technology that could collect and organize that kind of information.
More than a decade later, as the portfolio manager of an early-stage biotech investment fund, Garabedian is backing a company that’s looking to do just that.
VivoSense, a Newport Beach-based biometric data company, announced on Wednesday that it has raised $25 million in Series A funding co-led by Garabedian’s Perceptive Xontogeny Venture Fund and the Debiopharm Innovation Fund, the corporate venture arm of Swiss biopharma company Debiopharm. The new funding takes VivoSense to a total of $27 million raised to date..

VivoSense CEO Dudley Tabakin.
Photo courtesy of VivoSense
The startup collects and organizes data from biometric sensors that are used during clinical trials. The sensors track data like heart rate, breathing and bone density as participants use a drug, and provide valuable information to help understand how a drug affects a patient’s day-to-day life.
“There was a need to analyze that data and start using it to develop outcome measures that could be used in clinical trials by pharmaceutical companies,” VivoSense co-founder and CEO Dudley Tabakin told dot.LA.
The Series A funding will go towards building out VivoSense’s data technology for clinical trials, as well as for physicians who rely on remote monitoring technology to track patients who cannot visit the doctor as frequently.
“Pharmaceutical companies and biotechs should be proactively thinking about incorporating these types of methods into their clinical trials,” Garabedian told dot.LA. “It could make the difference between an approved drug or not.”
In 2020, the FDA revised its clinical trial standards after the pandemic kept people from leaving their homes, opening the door to a slew of companies tackling every aspect of a remote and distributed clinical trial system that still needs to be painstakingly accurate. El Segundo-based Lightship raised $40 million in September to create a fully-integrated virtual clinical trial setting, while Culver City-based Science 37 has received backing from large pharma companies like Thousand Oaks-based Amgen to make it easier for clinical trial conductors to find patients in a socially distant world.
From Your Site Articles
- Science 37 Aims to Take Clinical Trials to Homes - dot.LA ›
- MedVector's Hybrid Virtual Clinical Trials Aim for Accuracy - dot.LA ›
- Lightship Raises $40M to Speed Virtual Clinical Trials - dot.LA ›
- Topography Health Launches to Diversify Clinical Trials - dot.LA ›
Related Articles Around the Web
Read moreShow less
Keerthi Vedantam
Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.
https://twitter.com/KeerthiVedantam
keerthi@dot.la
Cap Tables to Costumes: Whatnot’s Mega Round and Your LA Weekend Plan 🎃
10:39 AM | October 31, 2025
🔦 Spotlight
Happy Friday Los Angeles!
Live shopping’s LA moment
Whatnot, the LA born marketplace for live auctions, raised $225 million at an $11.5 billion valuation. The round was co led by DST Global and CapitalG, with Sequoia, Alkeon, a16z, Greycroft, BOND, and others participating. The company says the money goes to international expansion, trust and safety, and seller tools - fuel for a category that has moved from “Is this a fad?” to “How big does this get in the West?”
Why it matters
If that valuation sounds sudden, you’re not imagining it. Whatnot’s last raise in January valued the company around $5 billion. Less than 10 months later, the number has more than doubled, tracking a year of surging GMV and a social commerce flywheel spinning across TikTok Shop, YouTube, and Amazon. For LA, it’s a marquee bet on the creator commerce stack we do best: community, content, and culture that converts
The bigger picture
The implications go well beyond trading cards. Live, personality led storefronts are evolving from hobby to underwritable small business. If Whatnot uses this cash to keep fraud low and throughput high, we could see an LA export take root globally, not just as an app category but as a job category. That is a storyline to watch into Q4 and beyond.
From cap tables to costumes: Halloween in LA 🎃
You’ve earned some offline fun. Heading into Halloween weekend (Oct. 31–Nov. 2), LAist’s guide has a little of everything: neighborhood Día de los Muertos celebrations (from the Canoga Park family festival to an ofrenda for pets at Annenberg PetSpace in Playa Vista), the Frogtown Arts weekend along the LA River, plus plenty of screenings and concerts across town. Bookmark the list, pick your neighborhood, and maybe swap “add to cart” for “add to calendar.”
Send tips, sightings, and spooky term sheets our way. Venture deals for LA companies, funds, and acquisitions are below.
🤝 Venture Deals
LA Companies
- Bryan Johnson’s longevity startup Blueprint raised $60M from a celebrity heavy group of backers including Kim Kardashian, Naval Ravikant, Alex Hormozi, Ari Emanuel, and the Winklevoss twins to turn Johnson’s personal Blueprint regimen into a broader consumer platform. The company says the funding will help package diagnostics, biomarker tracking, prescriptions, nutrition, and other longevity services into an accessible offering. The round underscores mainstream interest in data driven wellness despite past questions about Blueprint’s trajectory. - learn more
- Rarity PBC raised $4.6M in seed financing to advance a one-time, autologous blood-stem-cell gene therapy for ADA-SCID (“bubble baby” disease) that it has licensed from UCLA researcher Dr. Donald Kohn. The round, led by biotech investor Steve Oliveira (Nemean Asset Management), will support manufacturing and steps toward commercial readiness. - learn more
- Fruitist raised $150M led by a vehicle managed by J.P. Morgan Asset Management, with participation from Aliment Capital and Ray Dalio’s family office. The LA-based superfruit brand says the funding will fuel crop expansion, cold storage, and automation as it scales distribution to 12,500+ stores and targets continued growth following roughly $400M in trailing sales. - learn more
- Homecourt, the Los Angeles based luxury home and personal fragrance brand founded by Courteney Cox, raised an $8M Series A led by CULT Capital. The company says the funding will fuel brand marketing, team hires, and infrastructure as it expands beyond DTC into 300+ retail doors including Nordstrom, Bluemercury, and Revolve. Homecourt has broadened from home care into body and laundry collections since launching in 2022. - learn more
LA Venture Funds
- Aliavia Ventures participated in Human Health’s $8.5M raise, joining LocalGlobe, Airtree, Skip Capital and Scale Investors to back the precision health platform from former Canva product leaders Georgia Vidler and Kate Lambridis. The funding will support international expansion, deepen product intelligence in areas like women’s health, respiratory and pain, and scale Human Evidence for patient driven research; Human Health reports more than 200,000 users and 20 million logged health actions to date. - learn more
- Riot Ventures participated in EnduroSat’s $104M funding round, alongside Google Ventures, Lux Capital, the European Innovation Council Fund, and Shrug Capital. The Sofia based satellite manufacturer says the capital will scale production of its ESPA class (200 to 500 kg) modular satellite buses, targeting capacity of up to two satellites per day at a new 188,340 square foot Space Center so constellation customers can get to orbit faster. The raise is EnduroSat’s second this year and follows a €43 million round in May. - learn more
- Rocana Venture Partners participated in Recess’s $30M Series B, which was led by CAVU Consumer Partners and included Midnight Ventures, Torch Capital, Doehler Ventures, KAS Venture Partners, Vanquish, and Craig Kallman. The relaxation-beverage company will use the capital to grow its team, expand retail distribution, and ramp marketing, and it also named former Nutrabolt executive Kyle Thomas as President and Co-CEO to help scale the brand. Recess says it now sells in more than 15,000 U.S. stores, positioning it to capitalize on demand for functional relaxation and alcohol-alternative drinks. - learn more
- Terasaki Institute participated in iOrganBio’s $2M launch financing, joining First Star Ventures (lead), IndieBio, Cape Fear BioCapital, 2ndF, and Alix Ventures. The Chapel Hill based startup unveiled CellForge, an AI powered cell-manufacturing platform that pairs predictive models with high throughput control to engineer reproducible human cells and organoids for drug discovery and cell therapies. The funds support product development and early deployments. - learn more
- Fox Sports made a strategic investment in Shadow Lion, the creative agency and IP studio co-founded by Tom Brady, forming a partnership to develop talent-led originals, digital content, long-form projects, and marquee live events. The deal includes a new Los Angeles hub for Shadow Lion on the Fox lot, with early tentpoles including a University of Michigan football docuseries from executive producers Brady and Jim Harbaugh and collaboration on the Fanatics Flag Football Classic. - learn more
- EB Medical Research Foundation participated in Eliksa Therapeutics’ funding to advance ELK-003, a biological eye drop for ocular complications in epidermolysis bullosa. The round, led by DEBRA Research with support from Cure EB, the Abe Fund, and EB Research Partnership, backs an ongoing pilot study with 18 patients enrolled and no drug-related side effects reported among the first eight who completed treatment. - learn more
- Patron and HartBeat Ventures participated in Sweatpals’ $12M seed round alongside a16z speedrun, backing the community fitness platform as it expands its “daylife” model of IRL wellness events. The funding will support product and market expansion for hosts and gyms using Sweatpals for discovery, ticketing, memberships, and marketing. Business Insider reports the startup now reaches over 1 million monthly users and is growing into new U.S. cities. - learn more
- UP.Partners participated in Lula Commerce’s $8M Series A, led by SEMCAP AI with Rich Products Ventures, GO PA Fund, NZVC, Green Circle Foodtech Ventures, and Outlander VC also joining. The Philadelphia company, active with more than 2,000 retailers, offers an AI powered digital commerce suite for convenience stores covering order ahead, pickup, delivery, and back office tools, and says the round brings total funding to over $16M to meet rising demand. - learn more
- Navitas Capital led WorkHero’s $5M seed to scale its AI powered back office platform for small HVAC contractors, with Workshop Ventures, York IE, and strategic angels also participating. WorkHero combines agentic AI with human account managers to handle invoicing, permits, rebates, warranty registrations, and pricebooks so owners spend less time on admin. The funding will expand engineering and product and add new services such as call answering and bookkeeping. - learn more
LA Exits
- DMI was acquired by Stingray, adding about 8,500 U.S. retail locations to Stingray’s in-store audio advertising network and bringing its total footprint to roughly 33,500 sites. The deal cements Stingray’s leadership in pharmacy retail audio across the two largest chains and brings DMI’s creative services, including cinema advertising and brand marketing, under its umbrella, with CEO Tena Clark staying on to help integrate and expand the offering. - learn more
Read moreShow less
RELATEDTRENDING
LA TECH JOBS


